Question 1

What are nuclear receptors and why are they important drug targets?

Accepted Answer

Nuclear receptors are transcription factors that bind ligands such as hormones, lipids, and vitamins to alter gene expression. They regulate cellular pathways involved in reproduction, development, and metabolism. Nearly 15% of approved drugs target nuclear receptors, making them ideal therapeutic targets due to their ability to control vital cellular processes through small lipophilic ligands.

Question 2

How do Class I nuclear receptors differ from Class II nuclear receptors?

Accepted Answer

Class I nuclear receptors are cytosolic and bind steroid hormones, undergoing dimerization before translocating to the nucleus. Class II nuclear receptors exist in the nucleus as DNA-bound heterodimers with retinoid X receptors. Class I receptors recruit co-activators or co-repressors after binding DNA, while Class II receptors remain bound to co-repressors until a ligand causes their detachment and co-activator recruitment.

Question 3

What is the mechanism by which co-activators and co-repressors regulate gene transcription?

Accepted Answer

Co-activators recruit enzymes that unzip the DNA helix, allowing transcription machinery to access genes and initiate transcription. Co-repressors use enzymes to keep DNA tightly packed, blocking transcription. This chromatin remodeling mechanism allows nuclear receptors to either activate or suppress specific genes depending on which regulatory protein is recruited after ligand binding.

Question 4

How does tamoxifen demonstrate tissue-specific action as a selective estrogen receptor modulator?

Accepted Answer

Tamoxifen acts as an antagonist in breast tissue, blocking estrogen receptors to prevent cancer cell multiplication in ER-positive breast tumors. In bone tissue, the same drug acts as an agonist, activating estrogen receptors to preserve bone and increase bone density. This tissue-specific action exemplifies how selective estrogen receptor modulators can provide targeted therapeutic benefits.

Question 5

What genes do Class II nuclear receptors regulate and how do lipid-lowering drugs work?

Accepted Answer

Class II nuclear receptors control transcription of genes involved in lipid metabolism, glucose homeostasis, and inflammatory response. Fenofibrate, a lipid-lowering drug, binds Class II receptors like PPAR, causing co-repressor detachment and co-activator recruitment. This activates genes regulating fatty acid metabolism and decreases plasma triglyceride levels, demonstrating how drug-receptor interaction modulates metabolic pathways.

Question 6

What role do heat shock proteins play in Class I nuclear receptor activation?

Accepted Answer

Heat shock proteins bind to Class I nuclear receptors in the cytosol, keeping them monomeric and inactive. When a ligand binds the receptor, the heat shock protein dissociates, allowing the receptor to undergo homodimerization. This ligand-induced release of heat shock proteins is a critical step enabling the activated receptor dimer to translocate to the nucleus and bind DNA response elements.

Question 7

How do xenobiotic receptors affect drug metabolism and pharmacokinetics?

Accepted Answer

Xenobiotic receptors are Class II nuclear receptors that regulate expression of the drug-metabolizing enzyme CYP3A, which is responsible for the pharmacokinetics of approximately 60% of prescription drugs. By controlling CYP3A expression, xenobiotic receptors influence how quickly drugs are metabolized and eliminated from the body, affecting drug efficacy and safety profiles.

آلية المحول: المستقبلات النووية

Browse More Videos